Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients.

نویسندگان

  • Victor L Serebruany
  • Alex I Malinin
  • Dan Atar
چکیده

BACKGROUND Numerous randomized studies have shown that the combination of clopidogrel with aspirin yields better clinical outcomes than monotherapy in patients with acute vascular events. However, the impact of the aspirin dose on the antiplatelet potency of clopidogrel is unclear. We sought to compare the antiplatelet profile of aspirin 81 mg (n = 252) versus aspirin 325 mg (n = 459) before and during conventional clopidogrel loading (300 mg), and/or clopidogrel maintenance (75 mg/daily) therapy. METHODS Secondary post hoc analysis of an existing dataset consisting of 711 patients after coronary stenting (n = 601) and ischemic stroke (n = 110) treated previously with aspirin for at least 1 month, and then with aspirin + clopidogrel for at least 7 days was performed. Platelet assessments include conventional and whole blood aggregometry, rapid cartridge-based analyzers, and expression of platelet/endothelial cell adhesion molecule-1, P-selectin, and GPIIb/IIIa activity by flow cytometry measured before and after addition of clopidogrel. RESULTS There was a small but consistent yet non-significant trend towards more potent platelet inhibition with aspirin 325 mg compared to aspirin 81 mg for every platelet activation parameter before addition of clopidogrel. However, after loading and/or 1 week of chronic treatment with clopidogrel + aspirin, measured platelet parameters became very similar between the groups, and identical for collagen-induced aggregation and PFA-100 analyzer readings. CONCLUSIONS Before addition of clopidogrel, aspirin 325 mg has a tendency to provide stronger platelet inhibition than aspirin 81 mg. However, when clopidogrel and aspirin are used in combination, the higher aspirin dose does not translate into superior antiplatelet action. Given that the existing body of evidence supports the comparable efficacy and, particularly, superior safety of lower versus higher doses of aspirin, aspirin 81 mg should be the dose used in combination with clopidogrel.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Is Aspirin Still the Cornerstone of Antiplatelet Therapy in Patients With Coronary Artery Disease? An Historical and Practical Narrative Review

Aspirin is an irreversible and non-selective inhibitor of cyclo-oxygenase. It represents the cornerstone of antiplatelet therapy and is used in secondary prevention of cardiovascular disease. Disagreement over the optimal maintenance dosage still exists; in America and Europe the most used doses of aspirin are 81 mg and 100 mg daily, respectively. There is also debate on the formulation and rou...

متن کامل

Hemorrhagic events in patients receiving heparin or enoxaparin in combination with Oral antithrombotics, NSAIDs, and antiplatelet medications: A multi-center case-series study

Background: Hemorrhagic events are amongst the major adverse effects of injectable anticoagulants such as heparin and enoxaparin. This necessitates close monitoring of their use for clinically relevant drug-drug interactions. Aim: To study the rate of hemorrhagic events, the anatomical site, and the severity of the hemorrhage in patients receiving heparin or enoxaparin in combination with clop...

متن کامل

Does the combination of warfarin and aspirin have a place in secondary stroke prevention? No.

The role of combination therapy, whether antiplatelet or antithrombotic, in secondary stroke prevention is controversial. The only widely accepted combination therapy is clopidogrel plus aspirin in patients with coronary, carotid, or intracranial artery stents. The duration of combination antiplatelet therapy in stent patients is, however, controversial, with a minimum of 3 months used in most ...

متن کامل

Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial.

BACKGROUND Bleeding limits anticoagulant treatment in patients with acute coronary syndromes (ACS). OBJECTIVES We investigated whether background concomitant antiplatelet therapy influences the effects of apixaban after ACS. METHODS This study examined high-risk ACS patients who were treated with aspirin or aspirin plus clopidogrel and who were randomized to apixaban 5 mg twice daily or pla...

متن کامل

Prevalence of Aspirin Use among Type 2 Diabetic Patients in Iran

Abstract Objective: Patients with type 2 diabetes mellitus (DM) have a markedly increased risk of cardiovascular morbidity and mortality. There are some recommendations for prescription of aspirin in these patients. Our purpose was to determine aspirin usage rate in diabetic patients and to compare it in different ages and based upon cardiovascular disease (CVD) risk factors. Materials and M...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Cardiology

دوره 107 4  شماره 

صفحات  -

تاریخ انتشار 2007